Pulmocide will be presenting the Phase 1 data of novel anti-RSV agent, PC786, at ID week in San Francisco. The abstract entitled ” Safety and Pharmacokinetic Profile of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-protein Polymerase, in a Single and Multiple-Ascending Dose Study in Healthy Volunteer and Mild Asthmatics [abstract 1335]”, which session begins at 12:30 PM PDT on Friday 5th October, 2018.